U.S Food and Drug Administration (FDA) announced the availability of a draft guidance M15 General Principles for Model-Informed Drug Development. Developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), this draft guidance discusses the multidisciplinary principles of model-informed drug development (MIDD) and provides recommendations on MIDD planning, model evaluation, and evidence documentation.